Drugs / CZP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01451203 | Oct 2011 → Aug 2013 | rheumatoid arthritis | Astellas Pharma Inc | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CZP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01451203 ↗ |
| Route | Subcutaneous | “certolizumab pegol (CZP) subcutaneously” NCT01451203 ↗ |